1. Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background

3. Questions: 1987 Should…  persons attending STD clinics have a test for HIV antibody?  persons attending drug treatment programs have a test for HIV antibody?  the sexual partners of people with HIV infection be notified about their potential exposure and tested and counseled?

4. Questions: 1987 Should…  persons attending family planning services have a test for HIV antibody?  pregnant women have a test for HIV antibody as early in pregnancy as possible?  HIV antibody testing be a routine part of a premarital testing program?  Every patient admitted to a hospital be tested for HIV antibody?

5. Questions: 1987 How…  Can HIV antibody test results be used for appropriate medical and public health purposes without their being used for discrimination of social ostracism?

7. 1989 Recommendation No positive test results should be given to clients/patients until a screening test has been repeatedly reactive (i.e., two or more tests) on the same specimen, and a supplemental, more specific test such as the Western blot has been used to validate those results.

9. Proportion of persons who do not return for their HIV test results HIV PositiveHIV Negative 199525%33% 199626%33% 199733%42% 199838%44% 199943%48% 200042%47% Source: CDC Client Record Database, Publicly-funded HIV testing

10. 040,0000 2,000,000 1,442,847786,9371,147,25126,46522,514 1997 1,147,251 22,514 9,84327,9471,374,709 1996 708,2201,442,847 26,465 8,023 What if rapid HIV tests were used in all public testing sites? Additional, Rapid Test HIV Positive Current Strategy HIV Negative Additional, Rapid Test Current Strategy 1998 1,442,847856,8761,147,25126,46522,5141,091,045 18,118 9,843 1,442,847903,8391,147,25126,46522,514995,952 16,048 11,192 1999 1,442,847913,0571,147,25126,46522,5141,028,274 16,223 10,593 2000

12. 1998 Recommendation Health care workers should provide preliminary positive rapid test results before confirmatory results are available in situations where tested persons benefit.

13. Interpreting Screening Test Results For a laboratory test: Sensitivity : Probability test=positive if patient=positive Specificity : Probability test=negative if patient=negative Predictive value : Probability patient=positive if test=positive Probability patient=negative if test=negative

14. Example: Test 1,000 persons HIV prevalence = 10% True positive:False positive: Positive predictive value:100/104 = 96% 1004 Test Specificity = 99.6% (4/1000)

15. Example: Test 1,000 persons Test Specificity = 99.6% (4/1000) HIV prevalence = 10% True positive: 100False positive: 4 Positive predictive value: 100/104 = 96% HIV prevalence = 0.4% True positive:4False positive:4 Positive predictive value:4/8 = 50%

16. Predictive Value: Single Screening Test Test Specificity 99.8% HIV Prevalence True + False + Predictive Value Positive 10%100298% 5% 50 2 96% 2% 20291% 0.5% 5 2 71% 0.2% 2250% 0.1% 12 33% 1% 10 2 83%

17. Centrifuge to obtain serum or plasma

18. Several reagent steps

19. Blue color with reactive HIV test

21. Principle: Flow-through devices Microparticles immobilized in membrane form test spots HIV-1 peptide Control antibody: - Anti-IgG - Anti-gold

22. MedMira HIV 1-2

23. Reconstitute Conjugate with buffer

24. Add 1 drop buffer to cartridge

25. Add 1 drop serum to cartridge

26. Wash with buffer

27. Add conjugate to cartridge; wash

28. Read results immediately PositiveNegative

29. Immunochromatography Lateral Flow Devices –Determine –Doublecheck –HemaStrip –OraQuick –Unigold

30. Add Sample Conjugate C Control line T Test Line IgG Antibodies HIV antibodies Colloidal gold conjugated to HIV antigen Anti-IgG/gold antibodies HIV antigen Principle: Lateral flow devices

31. The anti-IgG/gold antibodies at the control line bind to any unbound colloidal gold particles forming a visible red band.The anti-IgG/gold antibodies at the control line bind to any unbound colloidal gold particles forming a visible red band. Specimen flows along the membrane and HIV antibodies (if present) bind to the HIV antigen conjugated to the colloidal gold forming a visible red band Principle: Lateral flow devices

32. OraQuick: Oral fluid, serum, whole blood

33. Obtain fingerstick blood specimen

34. Specimen loop with 5 microliters blood

35. Insert loop into vial and stir

36. Insert paddle into vial

37. PositiveNegative Reactive Control Positive HIV-1 Read results in 20 minutes

38. 2002 Consultation How…  can we maximize the use of rapid HIV tests?  can we maintain reliable, accurate test results?  can we use rapid tests to reach people who have not been tested?  do we accomplish all of these goals with a moderate complexity rapid HIV test?

39. Acknowledgements Ken Bell Lisa Pealer Tracey Hodges Ed Johns Barbara Triggs Ann Shuttleworth Laura Coker Beatie Divine Kim Lindsey Marie Morgan